Cellectar Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.70 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $2.18.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $2.69.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $8.70, a 89.34% decline from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $81.60, a 4484.27% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.78.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $1.66, a 9.78% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 98 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $8.70 10-K · filed 2026-03-04 | |||||||||||
| 2024-12-31 | $81.60 10-K · filed 2026-03-04 | $2.72 10-K · filed 2025-03-13 | ||||||||||
| 2023-12-31 | $1.78 10-K · filed 2025-03-13 | |||||||||||
| 2021-12-31 | $1.66 10-K · filed 2022-03-21 | |||||||||||
| 2021-03-04 | $17.40 10-K · filed 2023-03-09 | $1.74 10-K · filed 2022-03-21 | ||||||||||
| 2020-12-31 | $1.84 10-K · filed 2022-03-21 | |||||||||||
| 2019-12-31 | $2.33 10-K · filed 2021-03-02 | |||||||||||
| 2019-01-17 | $1.99 10-K · filed 2021-03-02 | $1.99 10-Q · filed 2019-11-12 | ||||||||||
| 2018-12-31 | $2.99 10-K · filed 2020-03-09 | |||||||||||
| 2018-10-12 | $2.61 10-K · filed 2021-03-02 | $2.61 10-Q · filed 2019-11-12 | ||||||||||
| 2018-06-30 | $11.70 10-Q · filed 2018-08-10 | |||||||||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-11 | |||||||||||
| 2017-12-31 | $1.91 10-K · filed 2019-02-26 | |||||||||||
| 2017-09-30 | $1.91 10-Q · filed 2017-11-09 | |||||||||||
| 2017-06-30 | $1.93 10-Q · filed 2017-08-14 | |||||||||||
| 2017-03-31 | $2.18 10-Q · filed 2017-05-11 | |||||||||||
| 2016-12-31 | $1.97 10-K · filed 2018-03-21 | |||||||||||
| 2016-09-30 | $1.97 10-Q · filed 2016-11-10 | |||||||||||
| 2016-06-30 | $1.48 10-Q · filed 2016-08-11 | |||||||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-12 | |||||||||||
| 2015-12-31 | $26.50 10-K · filed 2017-03-15 | |||||||||||
| 2015-09-30 | $2.65 10-Q · filed 2015-11-12 | |||||||||||
| 2015-03-31 | $2.69 10-Q · filed 2015-05-20 | |||||||||||
| 2014-12-31 | $36.90 10-K/A · filed 2016-10-20 | $3.69 10-K · filed 2015-03-24 | ||||||||||
| 2014-09-30 | $7.40 10-Q · filed 2015-11-12 | |||||||||||
| 2014-06-30 | $7.40 10-Q · filed 2015-08-12 | |||||||||||
| 2013-12-31 | $9.20 10-K · filed 2015-05-20 | $0.46 10-K · filed 2014-03-19 | ||||||||||
| 2013-09-30 | $0.43 10-Q · filed 2013-11-13 | $9.40 10-Q · filed 2015-05-20 | $0.47 10-Q · filed 2013-11-13 | |||||||||
| 2013-06-30 | $14.80 10-Q · filed 2014-08-04 | $0.74 10-Q · filed 2013-08-12 | ||||||||||
| 2013-03-31 | $0.74 10-Q · filed 2014-05-14 | |||||||||||
| 2012-12-31 | $0.75 10-K · filed 2014-03-19 | |||||||||||
| 2012-09-30 | $1.00 10-Q · filed 2013-11-13 | $1.00 10-Q · filed 2013-11-13 | ||||||||||
| 2011-12-31 | $1.16 10-K · filed 2013-03-28 | |||||||||||
| 2011-09-30 | $1.45 10-Q · filed 2012-11-06 | |||||||||||
| 2011-06-30 | $1.45 10-Q · filed 2012-08-09 | $1.45 10-Q · filed 2012-08-09 | ||||||||||
| 2010-12-31 | $2.36 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |